1 August 2011Jurisdiction reportsMichael Factor

SmithKline Beecham’s patent for rosiglitazone maleate (Avendia) upheld

Rosiglitazone maleate (Avendia) is a patented drug used for the treatment of type II diabetes, which is manufactured by SmithKline Beecham (SKB) (now GlaxoSmithKline).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

Douwe Egberts enjoys double shot over Nestlé in coffee patent rivalry

Never underestimate the ‘industry’ requirement in patent applications

Olympic IP: Sporting trademarks from a Swedish perspective

New practice on patentability of AI inventions in China

Powell Gilbert co-founder joins US firm's European push

The Eurasian Patent Organization: A growing attraction

Snell & Wilmer adds ex-Buchalter partner in LA

Technical prejudice in support of inventive step: A double-edged sword?

SmithKline Beecham’s patent for rosiglitazone maleate (Avendia) upheld

Editor's picks

Editor's picks

More articles